Ironwood Pharmaceuticals appointed William Huyett as chief operating officer and promoted Gina Consylman to SVP and chief financial officer.
As COO, Huyett will lead a range of functions, including finance, corporate strategy, development, communications, global operations, and investor relations. He was most recently senior partner emeritus at McKinsey and Company, where he worked with clients in the life sciences, industrial, and technology sectors for 30 years.
“Ironwood is poised for growth, thanks to strong commercial performance and an innovative, value-driven R&D approach,” said Huyett. “I’m excited to contribute toward sustaining and enhancing its trajectory.”
See also: Drugmakers eye growing IBS market with DTC push
Consylman, who joined Ironwood in 2014, is responsible for finance, planning, accounting, tax, treasury, and insurance functions. She previously held executive roles at Biogen and Analogic Corp.
“I’ve been fortunate to be a part of Ironwood’s growth over the past three years, and look forward to continuing to partner with our leadership team in this new role to support our financial and long-term strategic objectives,” said Consylman.
“Strengthening our leadership team with these key appointments is critical for Ironwood as we seek to execute on our strategy to deliver rapid top-line growth and advance our innovative mid- to late-stage product candidates,” said Ironwood CEO Peter Hecht in a news release.
See also: Facing a competitive market, Synergy looks to stand out with unbranded emojis
Ironwood’s products include gout drug Duzallo and Linzess for the treatment of irritable bowel syndrome.
This story has been updated.
From the January 01, 2018 Issue of MM+M - Medical Marketing and Media
